Previous studies documented olfactory dysfunction, also called postviral anosmia, following upper respiratory tract viral infections. Epithelial damage and the involvement of the central nervous system is identified as the possible causes but the exact pathogenesis remains unclear.^[@R1],[@R2]^ The association between the amount of anosmia, hyposmia, ageusia, and/or dysgeusia and COVID-19 patients was highly important. These signs' emergence may be sudden or slow. Results to date indicate the widespread prevalence of anosmia/hyposmia across the pandemic region, and a strong linear association between COVID-19 prevalence and olfactory impairment. Detailed neurological symptoms of the hospitalized COVID-19 patients are recorded in the analysis: 5% of patients had hyposmia, and of these patients, almost 3 quarter also had decreased sensation of taste.^[@R3]--[@R6]^

CLINICAL AND RESEARCH EFFECTS
=============================

On February 11, 2020, a taxonomic classification "severe acute respiratory syndrome coronavirus 2" (SARS-CoV-2) became the official way of referring to the 2019-nCoV and Wuhan coronavirus strain. The same day the WHO formally called the disease COVID-19 within a few hours. The SARS-CoV-2 genome is a coronavirus with 29.903 bp single-stranded RNA (ss-RNA). During April 2020, in parallel with the COVID-19 outbreak, the number of olfactory dysfunction patients in many reports has increased.^[@R4]--[@R6]^ This prompted the development of an online questionnaire to determine the prevalence of this olfactory condition. The COVID-19 Anosmia Reporting Tool for Clinicians was designed by the American Academy of Otolaryngology-Head and Neck Surgery in an attempt to determine the significance of these symptoms in the diagnosis and development of COVID-19.^[@R7]^ The association between the amount of anosmia, hyposmia, ageusia, and/or dysgeusia and COVID-19 patients was identified in all reports until April 2020. These signs' emergence may be sudden or slow. Results to date indicate the widespread prevalence of anosmia/hyposmia across the pandemic region, and a strong linear association between COVID-19 prevalence and olfactory impairment. Detailed neurological symptoms of the hospitalized COVID-19 patients are recorded in the analysis: 5% of patients had hyposmia and of these patients, almost 3 quarter also had a decreased sensation of taste. The onset of anosmia was abrupt in 76%, and continuously reduced sense of smell in 60% of patients until the time of completing the questionnaire. Of these patients, 83% also had decreased taste sensation in connection with anosmia. The latest high incidence of olfactory flu-related dysfunction (75%), higher incidence in women (71%), and high incidence of anosmia in family members (48.23%) indicate postviral olfactory dysfunction.^[@R4],[@R5],[@R8]^

Suzuki et al first detected rhinovirus, coronavirus, parainfluenza virus, and Epstein-Barr virus in the nasal secretion of patients with postviral olfactory disorders in 2007. Suzuki also reported that rhinoviruses can target olfactory impairment by means of mechanisms other than nasal obstruction, and that rhinoviruses may induce different olfactory dysfunction time courses.^[@R9]^ Various animal studies have demonstrated that various viruses may cause damage to central olfactory routes and other brain regions.^[@R10]--[@R12]^ Previous reports have not yet identified the neurological effects of COVID-19. Mao et al found that 36.4% of COVID-19 patients had a number of neurological symptoms including central nervous system, peripheral nervous system, and skeletal muscles. Detailed neurological symptoms of the hospitalized COVID-19 patients are recorded in the analysis: 5% of patients had hyposmia.^[@R8]^ It has been shown that the COVID-19 virus, similar to SARS-CoV, uses angiotensin-converting enzyme 2 (ACE2) receptor to obtain cell entry. This result increases the interest to examine the expression of ACE2 in neurological tissue, and to assess the possible contribution of neurological tissue damage to COVID-19 morbidity and mortality. To identify cell types in the olfactory epithelium that express molecules that mediate COVID-19 infection, Brann et al preliminarily reported bulk and single cell RNA-Seq datasets. Two primary genes necessary for COVID-19 entry, ACE2 and transmembrane serine protease 2, were shown in both animal and human datasets that olfactory sensory neurons do not express.^[@R13]^ For comparison, olfactory epithelial supporting cells and stem cells express none of these genes, as do cells in the epithelial nasal respiratory. Taken together, these results indicate possible mechanisms by which infection with COVID-19 may result in anosmia or other types of olfactory dysfunction.^[@R13]--[@R15]^

CONCLUSION
==========

The COVID-19 virus movement into the brain through the cribriform plate close to the olfactory bulb may be a mechanism that would enable the virus to reach and influence the brain. In addition, findings such as anosmia or hyposmia in an uncomplicated early COVID-19 patient will require a comprehensive central nervous system involvement assessment. Because olfactory dysfunction may affect the quality of life in patients affected, more clinical studies need to determine the exact correlation, pathogenesis, prognosis, and any connection between the seriousness of the disease and olfactory dysfunction worldwide. In the absence of other respiratory disorders, such as allergic rhinitis, acute rhinosinusitis, or chronic rhinosinusitis; anosmia, hyposmia, and dysgeusia will alert doctors to the possibility of COVID-19 infection and warrant serious consideration for self-isolation and testing of these individuals.
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